by Angelo DePalma, Ph.D., Childrens Health Defense:
Hospitalized patients who took hydroxychloroquine (HCQ) survived COVID-19 infections more frequently than those who did not, according to a study published this month in New Microbes and New Infections. While the retrospective study did not prove that HCQ cures COVID, its results justify further investigation into HCQ as part of a larger effort to manage the disease.
TRUTH LIVES on at https://sgtreport.tv/
Hospitalized COVID-19 patients treated with hydroxychloroquine (HCQ) alone, or HCQ plus the antibiotic azithromycin, had significantly lower mortality than those not receiving the drugs, according to a study released this month in New Microbes and New Infections.
Researchers in Belgium that just 16.7% of COVID-19 patients given HCQ, with or without azithromycin, died within 28 days compared to 25.9% among those not taking HCQ — a 35% lower mortality.
After adjusting for age differences, the risk of death was still 24% lower for HCQ-treated hospitalized patients.
The survival benefit was seen across all ages and was statistically significant.
The results support the efficacy of HCQ and azithromycin in improving outcomes for hospitalized COVID-19 patients. This contrasts with earlier studies using dangerously high HCQ doses that found no benefits.
Who participated in the study?
Led by Dr. Gert Meeus, a nephrologist at AZ Groeninge Hospital, Kortrijk, Belgium, researchers collected data from March 16 to May 20, 2020 — the first few months of the pandemic.
They compared outcomes for 352 COVID-19-positive, HCQ-treated adults hospitalized at AZ Groeninge Hospital with those of 3,533 patients across Belgium who did not receive the drug.
Treated patients averaged 69.7 years versus 73.1 years for the control group. While this age difference favors the younger subjects who face less risk from the virus, this factor was more than offset by the treatment group’s higher incidence of high blood pressure, diabetes, liver and lung diseases, and weakened immunity.
Treated subjects were also more obese — a COVID-19 risk factor — with lower blood oxygen (suggesting severe illness) and higher C-reactive protein levels. C-reactive protein is a blood marker for inflammation and poor COVID-19 outcomes.
During the 28 days following initial treatment, 16.7% of patients who received HCQ, either alone or with azithromycin, died compared with 25.9% in the control group.
How was HCQ administered?
For the study, 299 patients (85%) received HCQ plus azithromycin versus 53 who took HCQ alone. Researchers only prescribed the antibiotic when they suspected bacterial pneumonia. Data for HCQ alone and HCQ plus azithromycin were combined.
Subjects received HCQ as two 400-milligram doses on day one and two 200-milligram doses on days two through five.
Patients younger than 75 years received 500 milligrams of azithromycin for five days. Older patients took 500 milligrams on day 1 and 250 milligrams per day for four days.
88% of patients received the full treatment course but 12% took the drugs for less time, at the caregiver’s discretion, due to side effects or reaching a terminal condition.
Otherwise, side effects observed in 197 patients were mild and mostly stomach issues. One patient had hallucinations and two developed a skin rash.
Thirteen patients dropped out of the study due to side effects, including 4 of 15 who developed heart muscle abnormalities — despite an earlier study reporting an association between HCQ and lower cardiovascular risk.
Nine patients dropped out because of digestive upset. One patient developed an abnormal but nonfatal post-study heart rhythm, but no treated patients experienced sudden death or irregular heartbeat during the study.
Read More @ ChildrensHealthDefense.org
